International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026
(1998; 113 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAbstract
Ver el documentoAcknowledgments
Ver el documentoInformation on authors
Ver el documentoExchange rates used in the report
Abrir esta carpeta y ver su contenidoChapter 1: Policies for praziquantel*
Abrir esta carpeta y ver su contenidoChapter 2: Bayer & E. Merck: Discovery and development of praziquantel*
Abrir esta carpeta y ver su contenidoChapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea*
Abrir esta carpeta y ver su contenidoChapter 4: The Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation*
Abrir esta carpeta y ver su contenidoChapter 5: The international supply of praziquantel*
Cerrar esta carpetaChapter 6: Demand for praziquantel and national distribution*
Ver el documentoThe demand for praziquantel
Ver el documentoNational distribution of praziquantel
Ver el documentoReferences
Abrir esta carpeta y ver su contenidoChapter 7: Prices and production costs of praziquantel*
Ver el documentoOther documents in the DAP Research Series
Ver el documentoDAP Research Series No. 26
 

Chapter 6: Demand for praziquantel and national distribution*

* By Michael R. Reich and Ramesh Govindaraj, with assistance from John Norris, Christopher Mast, and Agnes Brinkmann.

This chapter provides an assessment of the global demand for praziquantel, and describes national distribution of the drug in several developing countries. The section on demand focuses on the striking gap between the high potential demand for the drug (as evidenced by the prevalence of schistosomiasis in developing countries), and its limited supply by the existing producers and formulators of the drug. The chapter also discusses the impact of praziquantel’s high cost on the operation of schistosomiasis control programmes. The section on distribution of the drug discusses: the role of international agencies and bilateral aid organizations in assisting national schistosomiasis control programmes; the role of the private market in ensuring the availability of the drug in developing countries; and the role and success of national schistosomiasis programmes (using the example of Mali) in making the drug available to people afflicted by the disease.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013